WCG will increase its scientific and regulatory capabilities through the acquisition of Intrinsic Imaging.
The deal, of which no financial details have been disclosed, sees WCG acquire medical imaging firm Intrinsic Imaging, adding services designed to support data integrity and reduce risk in clinical research.
“Patient imaging is used as a tool for measuring the effectiveness of the experimental drugs under investigation. Consider,” Donald Deieso CEO at WCG told Clinical Insider. “For example, the importance of documenting the shrinkage of tumors as a measure of efficacy of an oncology drug.”
He added: “WCG is committed to relieving the critical pain points that contribute needless delays and extra costs to clinical trials, which adversely affect patients in need of life saving interventions. Integrating imaging into our broad suite of specialty solutions will strengthen WCG’s impact on the clinical trial process.”
According to the firm, Intrinsic Imaging is the only company in the world to have five International Organization for Standardization (ISO) certifications to provide imaging core lab services for clinical trials.
Through the acquisition WCG will attain more than 500 board-certified physicians from Intrinsic Images.
The employees will also be experienced with supporting medical device, drug, and artificial intelligence (AI) clinical trials.
“WCG currently has over 4,000 individuals who support our global mission and activities,” Deieso told us. “Having acquired over 30 companies since founding WCG in 2012, we have had a successful track record effectively integrating companies into WCG.”
Intrinsic Imaging will now be known as WCG Intrinsic Imaging. The firm will keep the same leadership structure and will continue to run from its Bolton, Massachusetts facility.